Startup profile · funding coverage
Moonwalk Biosciences funding, valuation and investors
Biotech developing adipose-targeted RNAi medicines for obesity and cardiometabolic disease; raised $70 million Series B.
Keep track of Moonwalk Biosciences
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series B
$70M · September 8, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$70M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series b · South San Francisco, California, USA
Investors in latest funding
Lead: Alpha Wave , YK Bioventures
Other: Eli Lilly and Company , ARCH Venture Partners , Khosla Ventures
Overview
Moonwalk Biosciences develops adipose-targeted RNA interference medicines for obesity and cardiometabolic disease. On September 8, 2026 the company announced an oversubscribed $70 million Series B co-led by Alpha Wave and YK Bioventures.
Why Moonwalk Biosciences is interesting
Strong search demand and a differentiated obesity approach focused on adipose-selective RNAi rather than another GLP-1 program.
Key facts
- Sep 8, 2026: $70M Series B
- Lead program targets adipose tissue with RNAi for obesity
Funding history (newest first)
Series B
2026-09-08 $70M- Alpha Wave (lead)
- YK Bioventures (lead)
- Eli Lilly and Company (participant)
- ARCH Venture Partners (participant)
- Khosla Ventures (participant)
Market / IPO context
Editorial / static context — not a live quote.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.